Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

New Pediatric Labeling Information Database - Detail
  • Print
  • Share
  • E-mail
-
 
Pediatric Labeling Date:  07/21/2005
 
Trade Name:  Adderall XR
 
Generic Name or Proper Name (*):  amphetamines mixed salts
 
Indications Studied:  ADHD
 
Label Changes Summary:  Expanded labeling for 13-17 year olds On a mg/kg body weight basis children 6-12 years have a higher clearance than adolescents or adults. Body weight is the primary determinant There was not adequate evidence that doses greater than 20 mg/day conferred additional benefit in a placebo-controlled study conducted in adolescents aged 13-17 with ADHD In a single-dose PK study in adolescents, isolated increases in systolic blood pressure (SBP) were observed in patients receiving 10 mg and 20 mg Adderall XR. Higher single doses were associated with a greater increase in SBP Sustained increases in blood pressure should be treated with dose reduction and/or appropriate medication Information on dose, PK parameters, and AE profile
 
Product Labeling:  Labeling  Opens a new window
 
BPCA(B) and PREA(P):  B, P
 
Sponsor:  Shire
 
Pediatric Exclusivity Granted Date:  10/28/2004
 
NNPS:  FALSE'
 
Therapeutic Category:  CNS Stimulant
 
-
-